^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:OncoSignature® Test
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Acrivon TherapType:
Laboratory Developed Test
Evidence Level:
Sensitive: B - Late Trials
[No biomarker-Ovarian Cancer-ACR-368]
Source:
Test:
OncoSignature® Test
Title:
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
Published date:
05/09/2023
Excerpt:
Acrivon Therapeutics, Inc...announced that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer...One Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature® positive, locally advanced, or metastatic, recurrent platinum-resistant high-grade ovarian carcinoma who have received at least one prior systemic treatment regimen.
Evidence Level:
Sensitive: B - Late Trials
[No biomarker-Endometrial Cancer-ACR-368]
Source:
Test:
OncoSignature® Test
Title:
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
Published date:
05/09/2023
Excerpt:
Acrivon Therapeutics, Inc...announced that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer...The second Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature positive, recurrent high-grade endometrial cancer who have received at least two prior systemic treatment regimens.
